Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Accounts Payables (2016 - 2025)

Corcept Therapeutics' Accounts Payables history spans 10 years, with the latest figure at $40.4 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 163.03% year-over-year to $40.4 million; the TTM value through Dec 2025 reached $40.4 million, up 163.03%, while the annual FY2025 figure was $40.4 million, 163.03% up from the prior year.
  • Accounts Payables for Q4 2025 was $40.4 million at Corcept Therapeutics, up from $34.4 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $40.4 million in Q4 2025 and bottomed at $6.6 million in Q3 2021.
  • The 5-year median for Accounts Payables is $12.3 million (2022), against an average of $15.6 million.
  • The largest annual shift saw Accounts Payables tumbled 34.55% in 2021 before it skyrocketed 163.03% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $6.9 million in 2021, then skyrocketed by 73.36% to $12.0 million in 2022, then soared by 45.26% to $17.4 million in 2023, then decreased by 11.61% to $15.4 million in 2024, then skyrocketed by 163.03% to $40.4 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Accounts Payables are $40.4 million (Q4 2025), $34.4 million (Q3 2025), and $23.5 million (Q2 2025).